Lutathera from Novartis is indicated to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, which include foregut, midgut and handout neuroendocrine tumors in adults.
The drug was the focus of a recent presentation World Congress on Gastrointestinal Cancer 2021 where Dr. Jonathan R. Strosberg, presented positive survival data concerning the drug. Strosberg is the head of the Neuroendocrine Tumor Division and Department of Gastrointestinal Oncology Research Program at Moffitt Cancer Center in Tampa, Fla.
Specifically, the drug improved lengthened survival in patients with midgut neuroendocrine tumors in the Phase 3 trial known as NETTER-1 by 11.7 months.
Filed Under: Oncology